RecruitingNCT06683092
Restarting Triple Therapy With Robust Monitoring for Adverse Events (RETRIAL)
Studying Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Boston Children's Hospital
- Principal Investigator
- Anna Georgiopoulos, MDMassachusetts General Hospital
- Intervention
- RETRIAL-Mental Health(other)
- Enrollment
- 200 target
- Eligibility
- 6 years · All sexes
- Timeline
- 2025 – 2028
Study locations (18)
- University of Alabama at Birmingham, Birmingham, Alabama, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- Nemours Children's, Wilmington, Delaware, United States
- Nemours Children's, Jacksonville, Florida, United States
- Nemours Children's, Orlando, Florida, United States
- Nemours Children's, Pensacola, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Indiana University, Bloomington, Indiana, United States
- Kansas University Medical Center, Kansas City, Kansas, United States
- Johns Hopkins University, Baltimore, Maryland, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- Boston Children's Hospital, Boston, Massachusetts, United States
- University of Michigan, Ann Arbor, Michigan, United States
- Washington University at St. Louis, St Louis, Missouri, United States
- +3 more locations on ClinicalTrials.gov
Collaborators
Cystic Fibrosis Foundation · Johns Hopkins University · Massachusetts General Hospital · National Jewish Health · Indiana University · Children's Hospital Colorado · University of Kansas Medical Center · Washington University School of Medicine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06683092 on ClinicalTrials.govOther trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07071324CF Wellness ProgramJohns Hopkins University
- RECRUITINGNANCT07223255Gastrointestinal Response of Pediatric Cystic Fibrosis Patients on Mediterranean DietDartmouth-Hitchcock Medical Center
- RECRUITINGNANCT07031323OnTrackCF: Engagement, Feasibility, and Acceptability StudyBoston Children's Hospital
- ACTIVE NOT RECRUITINGNCT07147803Sleep Quality in Patients With Non-cystic Fibrosis BronchiectasisAssiut University
- RECRUITINGPHASE2NCT06998043Study With Phage for CF Subjects With Pseudomonas Lung InfectionBiomX Ltd
- RECRUITINGPHASE2NCT06559150A Phase II Study of Ensifentrine in Non-Cystic Fibrosis BronchiectasisVerona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
- RECRUITINGPHASE4NCT05704036Estrogen Supplementation and Bone Health in Women With CFJohns Hopkins University
- RECRUITINGNCT06274840COVID-19 Antibody Responses In Cystic FibrosisPilar Azevedo
See all trials for Cystic fibrosis-gastritis-megaloblastic anemia syndrome →